Special Issue

Drug Delivery Systems for the Combination Therapy of Cancer and Chronic Diseases

Message from the Guest Editors

Combination therapy has shown increased significance in clinical practice for cancers and many diseases, due to its promise in providing superior therapeutic and diagnostic benefits. This Special Issue aims to highlight and capture the recent progress and contemporary landscape of drug delivery systems in various dosage forms for combination therapy, including, micro- and nanoparticles, hydrogels and hybrid systems to mitigate the disease burden and minimize unwanted adverse effects. We are pleased to invite you to submit articles on all aspects of "Drug Delivery Systems Based on Combination Therapy of Cancer and Chronic Diseases". Research areas may include (but not limited to) the following: delivery technologies, therapeutic evaluations, and characterization (e.g., drug release and excipient selection) of drug combinations for small molecules, radiotracers, photosensitizers, proteins, and genes, as well as drug delivery system-assisted treatment schedules for patients with cancer and chronic diseases (e.g., Alzheimer's disease and eye diseases). Looking forward to receiving your contributions!

Guest Editors

Prof. Dr. Shirley X. Y. Wu

Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada

Dr. Ruixue Zhang

Institute of Medical Research, Northwestern Polytechnical University, 127 West Youyi Road, Xi'an 710072, China

Deadline for manuscript submissions

closed (20 January 2024)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/159971

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

